Evidence map›Paper›PMID 29164490›Full record

Trial reportImmunologic research2018

Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial).

Elena Chernykh, Olga Leplina, Ekaterina Oleynik, Marina Tikhonova, Tamara Tyrinova, Natalia Starostina, Alexandr Ostanin

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Immunologic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. A review of vaccinology andHuman vaccines & immunotherapeutics · 2025
    Review
  2. Review
  3. Review
  4. Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Elena ChernykhLaboratory of Cellular Immunotherapy, Institute of Fundamental and Clinical Immunology, 630099, Novosibirsk, Yadrintsevskaya str., 14, Russia.
Olga LeplinaLaboratory of Cellular Immunotherapy, Institute of Fundamental and Clinical Immunology, 630099, Novosibirsk, Yadrintsevskaya str., 14, Russia. oleplina@mail.ru.
Ekaterina OleynikLaboratory of Cellular Immunotherapy, Institute of Fundamental and Clinical Immunology, 630099, Novosibirsk, Yadrintsevskaya str., 14, Russia.
Marina TikhonovaLaboratory of Cellular Immunotherapy, Institute of Fundamental and Clinical Immunology, 630099, Novosibirsk, Yadrintsevskaya str., 14, Russia.
Tamara TyrinovaLaboratory of Cellular Immunotherapy, Institute of Fundamental and Clinical Immunology, 630099, Novosibirsk, Yadrintsevskaya str., 14, Russia.
Natalia StarostinaDepartment of the Clinic of Immunopathology of Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
Alexandr OstaninLaboratory of Cellular Immunotherapy, Institute of Fundamental and Clinical Immunology, 630099, Novosibirsk, Yadrintsevskaya str., 14, Russia.
Research Institute of Fundamental and Clinical Immunology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The key role of T cells in hepatitis C virus (HCV) elimination and the ability of dendritic cells (DCs) to induce antiviral T cell responses suggest that DC vaccines could be a promising approach in the treatment of chronic HCV infection. The aim of our study was to evaluate, whether immunotherapy with DCs is safe and elicits anti-HCV T cell responses. Ten patients with HCV (genotype 1) were vaccinated with monocyte-derived DCs, generated in the presence of IFN-α (IFN-DCs) and pulsed with recombinant HCV Core and NS3 proteins. Treatment schedule included four subcutaneous vaccinations with 1 week interval and six vaccinations with month interval. No serious adverse events or an increase in hepatitis C biochemical activity were registered after vaccination. Using ex vivo assays for the detection of proliferative responses, IFN-γ production and CD8

Indexed as

AdultCD8-Positive T-LymphocytesCells, CulturedDEAD-box RNA HelicasesDendritic CellsFemaleFollow-Up StudiesHepacivirusHepatitis C, ChronicHumansImmunotherapy, AdoptiveInterferon-alphaInterferon-gammaLymphocyte ActivationMaleMiddle AgedDEAD-box RNA HelicasesInterferon-alphaInterferon-gammaNS3 protein, hepatitis C virusNucleoside-TriphosphataseSerine EndopeptidasesViral Core ProteinsViral Nonstructural ProteinsViral ProteasesAntigen-specific T cell responsesCoreDendritic cellsHCV infectionImmunotherapyNS3

Identifiers

PMID29164490
OpenAlexW2770185281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.